Metabolic features of melanoma: a gold mine of new therapeutic targets?
In recent years, our knowledge regarding the metabolism of melanoma has greatly advanced and consequently new therapeutic strategies are being developed. This review is focused on metabolic pathways contributing to melanoma proliferation, the influence of BRAF inhibitors on those metabolic pathways and finally a presentation of potential therapeutic strategies aimed at blocking metabolic signaling pathways and therefore melanoma development.
Philippe
P
Marchetti
Pierre
P
Guerreschi
Jérôme
J
Kluza
INSERM U 837 Faculte de Medecine, 1, place Verdun F- 59045 Lille Cedex, France. philippe.marchetti@inserm.fr.
Laurent
L
Mortier
D000596:Amino Acids / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006019:Glycolysis / Q000187:drug effects; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D012867:Skin / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism
D000596:Amino Acids; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins